A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 32, Issue 4, 2012, Pages 551-557

  Ibrahim, Lobna ^a   Diazgranados, Nancy ^a,b   Jolkovsky, Libby ^a   Brutsche, Nancy ^a   Luckenbaugh, David A ^a   Joseph Herring, W ^c   Potter, William Z ^c   Zarate Jr , Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Depression; Glutamate; NMDA; NR2B; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; MK 0657; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MONOTHERAPY; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CROSS-OVER STUDIES; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84863719297     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31825d70d6     Document Type: Article

References (35)

1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. (Pubitemid 43050100)
2. Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry. 2008;69(6): 946-958. (Pubitemid 351944948)
3. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292(3):338-343. (Pubitemid 38944257)
4. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4): 351-354. (Pubitemid 30109248)
5. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793-802.
6. Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28(6):631-637.
7. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. (Pubitemid 44188478)
8. Valentine GW, Mason GF, Gomez R, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011;191(2):122-127.
9. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139-145.
10. Sanacora G, Zarate CA, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7(5):426-437. (Pubitemid 351619114)
11. Machado-Vieira R, Manji HK, Zarate CA. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist. 2009;15(5):525-539.
12. Feyissa AM, Chandran A, Stockmeier CA, et al. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(1):70-75.
13. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-964.
14. Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63(4):349-352. (Pubitemid 351146651)
15. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: New York State Psychiatric Institute, Biometrics Research; 2001.
16. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):10-17.
17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
19. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974;7:151-169.
20. Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969;62(10):989-993.
21. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
22. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
23. Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11(1):125-136. (Pubitemid 28097797)
24. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133: 429-435. (Pubitemid 9006756)
25. Snaith RP, Hamilton M, Morley S, et al. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99-103. (Pubitemid 26124582)
26. Addy C, Assaid C, Hreniuk D, et al. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. J Clin Pharmacol. 2009;49(7):856-864.
27. Machado-Vieira R, Yuan P, Brutsche N, et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry. 2009;70(12):1662-1666.
28. Max MB. Small clinical trials. In: Gallin JI, ed. Principles and Practice of Clinical Research. New York, NY: Academic Press; 2002: 207-224.
29. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008;64:527-532.
30. Faries D, Herrera J, Rayamajhi J, et al. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res. 2000;34:3-10. (Pubitemid 30006935)
31. Mallinckrodt CH, Meyers AL, Prakash A, et al. Simple options for improving signal detection in antidepressant clinical trials. Psychopharmacol Bull. 2007;40:101-114.
32. Bech P, Allerup P, Gram LF, et al. The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand. 1981;63:290-299. (Pubitemid 11137960)
33. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand. 1975;51:161-170.
34. Borza I, Bozo E, Barta-Szalai G, et al. Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J Med Chem. 2007;50(5):901-914. (Pubitemid 46393993)
35. Suetake-Koga S, Shimazaki T, Takamori K, et al. In vitro and antinociceptive profile of HON0001, an orally active NMDA receptor NR2B subunit antagonist. Pharmacol Biochem Behav. 2006;84(1): 134-141. (Pubitemid 43975558)